Journal of Cardiac Failure
Volume 16, Issue 11 , Pages 873-879 , November 2010

Serum YKL-40 Predicts Adverse Clinical Outcomes in Patients With Chronic Heart Failure

  • Olga Bilim, MD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Yasuchika Takeishi, MD, PhD

      Affiliations

    • Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan
    • Corresponding Author InformationReprint requests: Yasushika Takeishi, MD, PhD, Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. Tel: +81-024-547-1190.
    • ,
  • Tatsuro Kitahara, MD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Mitsunori Ishino, MD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Toshiki Sasaki, MD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Satoshi Suzuki, MD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Tetsuro Shishido, MD, PhD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata
    • ,
  • Isao Kubota, MD, PhD

      Affiliations

    • First Department of Internal Medicine, Yamagata University School of Medicine, Yamagata

Received 18 January 2010 ,Revised 3 May 2010 ,Accepted 28 May 2010.

References 

  1. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure—the whys and wherefores. Heart Fail Rev. 2006;11:83–92
  2. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003;348:2007–2018
  3. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  4. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711
  5. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206
  6. Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure—possible role of platelets and monocytes. Cardiovasc Res. 2000;45:428–436
  7. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75–81
  8. Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–509
  9. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–225
  10. Johansen JS, Stoltenberg M, Hansen M, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford). 1999;38:618–626
  11. Volck B, Price PA, Johansen JS, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351–360
  12. Johansen JS, Olee T, Price PA, Hashimoto S, Ochs RL, Lotz M. Regulation of YKL-40 production by human articular chondrocytes. Arthritis Rheum. 2001;44:826–837
  13. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999;250:168–173
  14. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients?. Cancer Epidemiol Biomarkers Prev. 2006;15:194–202
  15. Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD. YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin Diagn Lab Immunol. 2002;9:598–604
  16. Kronborg G, Ostergaard C, Weis N, et al. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand J Infect Dis. 2002;34:323–326
  17. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol. 2003;39:179–186
  18. Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55:221–227
  19. Register TC, Carlson CS, Adams MR. Serum YKL-40 is associated with osteoarthritis and atherosclerosis in nonhuman primates. Clin Chem. 2001;47:2159–2161
  20. Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687–694
  21. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis. 2007;18:391–396
  22. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res. 2006;55:53–59
  23. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95:3C–8C
  24. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108:2905–2910
  25. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation. 2004;110:2869–2874
  26. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731–733
  27. Conrozier T, Carlier MC, Mathieu P, et al. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study. Ann Rheum Dis. 2000;59:828–831
  28. Johansen JS, Krabbe KS, Moller K, Pedersen BK. Circulating YKL-40 levels during human endotoxemia. Clin Exp Immunol. 2005;140:343–348
  29. Johansen JS, Pedersen AN, Schroll M, Jorgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol. 2008;151:260–266
  30. Bergmann OJ, Johansen JS, Klausen TW, et al. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res. 2005;11:8644–8652
  31. Nojgaard C, Host NB, Christensen IJ, et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis. 2008;19:257–263
  32. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3–S9
  33. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  34. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79–87
  35. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J. 2004;380:651–659
  36. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem. 2006;281:21082–21095

 This study was supported in part by Grant-in-aid for Scientific Research (No. 21590935) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and Grants from the Takeda Science Foundation, the Uehara Memorial Foundation, and Fukuda Foundation for Medical Technology.

 See page 878 for disclosure information.

PII: S1071-9164(10)00253-8

doi: 10.1016/j.cardfail.2010.05.029

Journal of Cardiac Failure
Volume 16, Issue 11 , Pages 873-879 , November 2010

Article Tools

* Image Usage & Resolution